Entrepreneurs-in-Residence and Atlas Advisors
Atlas Advisor; Co-Founder and Chief Operating Officer, Generation Bio
Mark is co-founder and chief operating officer of Generation Bio. Previously, he was senior vice president of pharmaceutical sciences and rare disease franchise head at bluebird bio Inc. Before bluebird, Mark was senior director of research and development and site head in Cambridge, Massachusetts for Baxter Healthcare Corporation. Previously, Mark worked at Archemix, Momenta Pharmaceuticals, Millennium Pharmaceuticals, and DuPont Pharmaceuticals. His experience spans from development through commercialization including the first commercial launch for a bioequivalent (generic Lovenox™), the ANDA submission for generic Copaxone™, the sNDA for Integrilin™, and numerous INDs across small-molecules, biologics, peptides, complex mixture, and gene therapy products. Mark holds a PhD and MS from MIT, and a BS from The Cooper Union.
Atlas Advisor; Chief Executive Officer, Lysosomal Therapeutics, Inc.
Kees is CEO of Lysosomal Therapeutics Inc (LTI). He was formerly CEO of EnVivo Pharmaceuticals (later renamed FORUM Pharmaceuticals) for eight years where he successfully built a respected neuroscience biotech company that advanced several NCE drug compounds into the clinic for cognition improvement in Alzheimer's and schizophrenia. He previously spent four years at Biogen, where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development. Kees holds an MBA from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering.
Venture Partner; Chief Executive Officer, Triplet Therapeutics; Chairman, Akrevia Therapeutics, F-star
Nessan is CEO of Triplet Therapeutics, and serves as chairman of Akrevia Therapeutics and F-star. He co-founded and was previously chief executive officer of Intellia Therapeutics, which he led from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Atlas Advisor; Chief Scientific Officer, Co-Founder, Accent Therapeutics
Bob is President, CSO and Co-Founder of Accent Therapeutics, board director at Disarm Therapeutics, and President of Ki Consultant, LLC. He was formerly President of Research and CSO of Epizyme and before that, VP of Cancer Biology at GlaxoSmithKline. He has contributed to drug discovery and development efforts leading to 18 investigational new drugs entering human clinical trials. Bob has authored more than 200 scientific publications, 5 books, and holds 13 issued U.S. patents. In 2016 he was elected a Fellow of the American Association for the Advancement of Science (AAAS). Bob received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology.
Atlas Advisor; President and Head of R&D, Cadent Therapeutics
Mike is president and Head of R&D of Cadent Therapeutics. Prior to joining Atlas Venture and Cadent, Mike spent over twenty years in pharma, including in research and development roles at Bristol-Myers Squibb and Infinity Pharmaceuticals. He has led multidisciplinary research and development teams and advanced eight compounds from discovery to clinical studies across several therapeutic areas. In addition, Mike was involved with advancing four compounds through late stage development, resulting in three regulatory approvals.
Atlas Advisor; Chief Scientific Officer, Disarm Therapeutics
Raj is CSO of Disarm Therapeutics and board director at Indalo Therapeutics. Previously he was chief scientific officer of Padlock Therapeutics until its sale to BMS in March 2016. Raj previously served as president and chief executive officer of Euclises Pharmaceuticals and senior vice president of Deciphera Pharmaceuticals. Prior to that, he was senior vice president of Jubilant Drug Discovery & Development. Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and legacy Pharmacia and Searle companies. He has led multiple discovery & early clinical development teams that have advanced eight candidates into clinical trials for refractory cancers, rheumatoid arthritis, diabetic nephropathy, COPD, and pain.
Entrepreneur-in-Residence; Head of R&D, Sophren
Judy is an EIR focused on identifying new treatments in psychiatry. Prior to Atlas, Judy was Vice President of Clinical Development at Roche in Basel, Switzerland and Head of Roche Innovation Center in NYC. She has held leadership positions in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor. Judy attended Wesleyan University and the University of Rochester, obtaining undergraduate and graduate degrees in Neurobiology. She completed research fellowships in Neuropharmacology at the Center for Brain Research at Strong Memorial Hospital and in Clinical Research at Pfizer. She has served on the Scientific Advisory Board of the TRI—TDI and is an advisor to the Empire Discovery Institute.
Atlas Advisor; SVP, Head of Neuropharmacology and Translational Sciences, Disarm Therapeutics
Tom is SVP, head of pharmacology and translation at Disarm Therapeutics. He has 25 years of pharmaceutical research and development experience focused on therapeutics for neurodegenerative disorders. Prior to joining Disarm, Tom was in the Center for External Innovation at Takeda and the Neuroscience Research Unit at Pfizer. The majority of his career in industry was spent at Biogen, where he led projects in Alzheimer’s disease, Parkinson’s disease and neuropathic pain at the discovery and early clinical development stages. Tom’s first industry position was at Cephalon after completing a postdoctoral fellowship and several years in a tenure track position at NINDS. He obtained his PhD in pharmacology and BA in biology from the University of Pennsylvania.
Atlas Advisor; Chief Business Officer, Replimune
Pamela is chief business officer of Replimune. Previously she served as CBO at Ra Pharmaceuticals which she helped transform from a discovery platform to a clinical stage company and ultimately raising approximately $58 million in a Series B/mezzanine financing. Prior to Ra, she was VP of business development at Biovex and was responsible for negotiating the acquisition of the company by Amgen in 2011 for $1 billion. Biovex’s drug, Imlygic (T-VEC), was approved in the US, Europe and Australia in 2015. Previously, Pamela held business development, strategy and commercial roles at several clinical stage biotechnology companies including Bioduro, Vion and Angiochem. Pamela holds a BA from Dartmouth College and a PhD from Tufts Medical School.
Atlas Advisor; Chief Executive Officer, Magenta Therapeutics
Jason is chief executive officer of Magenta Therapeutics. He was Head of GSK R&D Satellite in Boston, and created and led the Regenerative Medicine Unit where he ran internal programs and established external partnerships, including stem cell gene therapies. Jason was also Head of GSK’s Center of Excellence for External Drug Discovery and led a team that identified, established and managed alliances with world-leading biotech companies. He has worked on multiple successful modalities across a range of therapeutic areas from target to launch, including the NDA approval for Tykerb in breast cancer. He was formerly a scientist at Progenics Pharmaceuticals and Chiron, and was educated at Cambridge, Oxford and Harvard Universities.
Atlas Advisor; Former Chief Executive Officer, Obsidian Therapeutics
Mike was formerly chief executive officer of Obsidian Therapeutics. Previously, he was chief executive officer of Atlas portfolio company Padlock Therapeutics until its sale to BMS in March 2016. Prior to (re-)joining Atlas Venture in 2013, Mike was the founder and CEO of Atlas portfolio company Stromedix, which was sold to Biogen Idec in 2012. Previously, he led all discovery research activities at Biogen Idec. Before that, Mike served as chief scientific officer of ARIAD Pharmaceuticals and on the scientific staff at Cold Spring Harbor Laboratory.
Atlas Advisor; Founder and Executive Chairman, IFM Therapeutics
Gary is founder and executive chairman of IFM Therapeutics. In 2006, Gary founded Lycera Corp. to discover breakthrough medicines for autoimmunity and cancer. Under his direction, Lycera partnered three programs with Merck & Co., advanced LYC-30937, a modulator of the mitochondrial ATPase based directly on research from his academic lab, into clinical trials for inflammatory bowel disease, and established and drove Lycera’s immune-oncology platform. Gary trained at Columbia and Harvard and has been on the chemistry faculty at the University of Michigan in Ann Arbor since 1990. He has authored over 100 peer-reviewed papers and is the inventor on 27 issued U.S. patents.
Atlas Advisor; Co-Founder and Chief Scientific Officer, HotSpot Therapeutics
Gerry is Co-Founder and CSO of HotSpot Therapeutics. She brings more than 20 years of experience in various leadership roles in Boston biotech. Prior to founding HotSpot, Gerry was Vice President and Head of the Nimbus Apollo subsidiary at Nimbus Therapeutics where she led the effort to develop a leading NASH drug currently in Phase II. This culminated in subsidiary acquisition by Gilead. Prior to Nimbus, Gerry was Vice President at Galenea Pharmaceuticals, co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals and was a member of the founding scientific team at LeukoSite. Gerry received her Ph.D. in Chemistry at the University of Rhode Island and completed her post-doc fellowship at The University of Kansas.
Atlas Advisor; Chief Executive Officer, Zafgen
Jeff is an Atlas Advisor and CEO of Zafgen. Previously he was president and chief executive officer of Vitae Pharmaceuticals prior to its acquisition by Allergan in 2016. Prior to joining Vitae Pharmaceuticals, Jeff worked at Bristol-Myers Squibb in a variety of executive positions, including: senior vice president of BMS’s virology and immunology divisions, where he was responsible for all aspects of the $1 billion business; president and general manager, Canada; and vice president, U.S. managed health care. While at BMS, Jeff was directly associated with several product successes, including Pravachol®, Plavix®, Avapro®, Abilify®, Reyataz®, and Atripla®.
Atlas Advisor; Chief Executive Officer, Navitor
Tom is chief executive officer of Navitor. He has over 25 years of experience in pharmaceutical research and development. Previously, Tom served as chief executive officer and chief scientific officer of Zafgen. From 1987 until 2008, Tom held several positions at Novartis AG including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research. Tom has authored over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity. Tom also serves as a director on the board of Miragen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Atlas Venture portfolio company Nimbus Therapeutics.
Atlas Advisor; Chief Medical Officer, Replimune
Howard is CMO of Replimune and is a leader in the development of oncolytic viruses for the treatment of cancer. Prior to joining Replimune, he served as the Chief of Surgical Oncology at the Albert Einstein College of Medicine, the Chief of Surgical Oncology at Columbia University, Associate Director of the Herbert Irving Comprehensive Cancer Center, and Director of the Rush University Cancer Center in Chicago. Howard has published over 500 peer-reviewed manuscripts, books and scientific abstracts dedicated to oncolytic immunotherapy. He completed his BS summa cum laude at the University of Illinois Chicago and medical school at Loyola University. His was a resident at Boston University and is a fellow of the American College of Surgeons.
Atlas Advisor; Chief Scientific Officer, Bicycle Therapeutics
Nick is CSO of Bicycle Therapeutics. Previously he served as the Cambridge (US) head of oncology research at Novartis, leading a group that delivered multiple new therapies to the clinic and built industry-leading platforms for drug development. Prior to Novartis, Nick held positions of increasing responsibility at AstraZeneca, most recently leading the US oncology lead generation group; and was instrumental in the acquisition of KuDOS Pharmaceuticals leading to the registration of Olaparib (a first in class PARP inhibitor) for the treatment of BRCA mutant cancers. Nick studied Natural Sciences at the University of Cambridge and was a graduate student with the ICRF in Cambridge. He completed his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.
Atlas Advisor; Chief Development Officer, Generation Bio
Doug is chief development officer at Generation Bio. Previously, he ran Shire’s rare neuroscience franchise, including BD/portfolio management, transition into development and all clinical activity. Prior to that, Doug worked at Biogen as the global lead for a series of programs in Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). He was the global lead for Biogen’s nusinersen (Spinraza), the first approved drug for SMA. Doug has over 120 publications in medical journals. He received his MD and PhD from Jefferson Medical College; his MBA from Northeastern; and his B.A. from Princeton. He completed his neurology residency at The Johns Hopkins University School of Medicine and subsequently served as an Associate Professor of Neurology.
Entrepreneur-in-Residence; Chief Scientific Officer, Quench Bio
Iain is an EIR and the CSO at Quench Bio. Previously he served as VP Preclinical Biology in the Inflammation and Immunology Research Unit at Pfizer where he was responsible for a portfolio of both small and large molecule programs targeted across rheumatology, dermatology and gastroenterology. Iain had a 22 year tenure at Pfizer, starting as an internal industrial postdoc and taking on roles of increasing responsibility working across the drug discovery paradigm from target identification to leading the early clinical cluster in Rheumatology and Dermatology. Iain graduated with a BA and MA Cantab in Biochemistry from Jesus College, University of Cambridge before completing his PhD in the Breast Cancer Research Laboratories at the University of Liverpool.
Atlas Advisor; Chief Executive Officer and Co-Founder, Arkuda Therapeutics
Gerhard is CEO and Co-Founder of Arkuda Therapeutics. Formerly he was CEO and president of Quartet Medicine. Prior to Quartet, he was Chief Scientific Officer and Senior Vice President of FORUM Pharmaceuticals where he developed a CNS-focused pipeline of small molecule therapeutics ranging from discovery-stage programs to phase 3 clinical programs. Prior to FORUM, Gerhard was Vice President, Scientific Programs and Evaluation for Fidelity Biosciences Group (now F’ Prime Capital). Before that, Gerhard was Director of the Dementia Research Department at Bayer. Gerhard has co-authored major scientific publications, patents, and reviews of new research findings in prestigious journals. He received his MS with honors and his PhD in Neurobiology, graduating summa cum laude from the University of Heidelberg, Germany.
Atlas Advisor; Co-Founder and VP, Head of Biology, Disarm Therapeutics
Raul is VP, Head of Biology and co-founder of Disarm Therapeutics. He was previously Co-Head, North America, of the Neurology Disease Area Team at Vertex Pharmaceuticals, leading a strategic and scientific committee responsible for all early stage Neurology Programs. He was also the Multiple Sclerosis Disease Area Expert. Experienced in forming and leading early discovery teams, he was a major contributor to CNS projects involving axo-glial communication, myelination, glial biology, and axonal degeneration and protection. Raul previously was Director of Neurosciences at AlphaGene, and held roles in discovery research at Biogen-Idec and Genetics Institute/Wyeth. He earned his PhD in Neurobiology from Harvard University, with Gerald Fischbach, followed by a postdoctoral fellowship at Harvard Medical School.
Atlas Advisor; President & Chief Executive Officer, AVROBIO
Geoff is president & chief executive officer of AVROBIO. Previously Geoff was CEO of Organogenesis Inc which treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Geoff was founding CEO of eGenesis Inc., which applies CRISPR-Cas 9 gene editing to the field of xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts.
Atlas Advisor; President and Chief Executive Officer, Spero Therapeutics
Ankit is co-founder, president, and chief executive officer of Spero Therapeutics. Ankit was previously a venture partner at Atlas Venture. Prior to that, he worked in business development at Genentech, in health policy in Washington, and helped build several early stage biotech companies including Arcion Therapeutics. Ankit obtained his MD from John Hopkins University Medical School and his MBA from Wharton School at the University of Pennsylvania.
Atlas Advisor; Chief Scientific Officer and President, Kymera Therapeutics
Nello is a founder, chief scientific officer, and president at Kymera Therapeutics. Previously, Nello was head of drug discovery at Atlas portfolio company Raze Therapeutics. Before that, Nello spent almost a decade at the Novartis Institutes for Biomedical Research, where first as team member and then as interdisciplinary project team leader he contributed to the identification of more than 10 compounds that have entered preclinical and clinical development. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver development candidates. Nello has authored multiple peer-reviewed publications; he is co-inventor on several patents and has written reviews in the areas of synthetic chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute.
Atlas Advisor; Chief Executive Officer, Ikena Oncology
Mark is Chief Executive Officer of Ikena Oncology and has nearly two decades of experience in cancer biology. Mark was previously Vice President, Oncology Biology at Takeda Pharmaceuticals where he led the Oncology Biology group and was a member of the senior R&D management team responsible for the global oncology R&D strategy. During his time at Takeda the Oncology organization put 8 novel mechanisms into the clinic with the most advanced compounds being in phase 3 clinical development. Mark received his BS from the University of Rhode Island and earned his PhD in Biology from Boston College.
Atlas Advisor; Chief Executive Officer and President, Miragen Therapeutics
Bill is miRagen’s president, chief executive officer, co-founder, and director. Bill was previously vice president of technology and business development for bioscience at Thermo Fisher Scientific where he led the Thermo Fisher Biosciences Division. Prior to that Bill was a scientific founder and executive vice president of Dharmacon, Inc. Earlier, Bill served in many capacities at Amgen, Inc., most recently as associate director of research, site head for research, and head of the nucleic acid and peptide technology department.
Atlas Advisor; Chief Executive Officer, Generation Bio
Geoff is CEO of Generation Bio. He formerly served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 - 2017. Prior to Sobi Geoff held a variety of senior roles at Genzyme Corporation, including President of Genzyme Europe and SVP and GM of the global Lysosomal Storage Diseases business. Geoff has a B.Sc. in Biology and a B.A. in Philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained an M.D. at Harvard Medical School and completed his residency training in Internal Medicine and Pediatrics at Massachusetts General Hospital and Boston Children's Hospital.
Vic is an EIR at Atlas. Previously he was chief technology officer of Editas Medicine where he led the genome editing platform as well as the chemistry, CMC and quality departments. He has more than 20 years of experience in the biotech industry. At the Novartis Institutes for Biomedical Research he led a large, technology focused target discovery, target validation and lead finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Vic focused on industrializing and using ‘omics technologies at Millennium, Akceli and Corning. He has B.S. from Cornell, a Ph.D. from Yale and did his post-doc at MIT/The Whitehead.
Atlas Advisor; Chief Executive Officer, HotSpot Therapeutics
Jonathan is Co-Founder and CEO of HotSpot Therapeutics. Prior to HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics where he helped to establish the company's drug discovery platform and progressed multiple programs through a series of transactions and collaborations. This culminated in transactions with Gilead, Shire, and Monsanto. Previously, Jonathan was Vice President, Business Development at Concert Pharmaceuticals where he was instrumental in securing a $1B multi-product transaction with GSK. Jonathan trained as a chemist with Jack Baldwin at Oxford University, KC Nicolaou at The Scripps Research Institute, and Paul Nurse at Cancer Research UK.
Entrepreneur-in-Residence; CEO, Vedere
Cyrus is an EIR with Atlas and CEO of Vedere. Prior to Atlas, he was co-founder of CODA Biotherapeutics, and Oncorus, where he served as President and CBO. Before Oncorus, Cyrus was VP and global head of business development and alliance management at bluebird bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program in collaboration with Celgene, and a successful IPO. Cyrus earned his Sc.B. in neuroscience from Brown University, his M.D. from the University of Virginia School of Medicine and his MBA from the Kellogg Graduate School of Management at Northwestern University. He is a licensed physician, and a Fellow of the Academy of Wilderness Medicine.
Atlas Advisor; Former Chief Executive Officer, Nimbus Therapeutics
Don was formerly CEO of Nimbus Therapeutics. He previously spent 25 years at Merck where he held various strategic, leadership and operational roles in diverse therapeutic areas. Don began his pharma-therapeutics career in 1988 as a bench scientist at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility, most recently as Worldwide Discovery Head for Bone, Respiratory, Immunology and Endocrine disorders. Don has co-authored over 150 scientific publications and is internationally-recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council post-doctoral fellow at the University of Munich in Germany.
Atlas Advisor; Chief Scientific Officer, Surface Oncology
Vito is CSO at Surface Oncology. Vito brings over twenty years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations. Previously, he was EVP and CSO at Infinity Pharmaceuticals. Before that, he was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals, Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, and also held a number of positions at LeukoSite and ProScript. Vito was involved in the discovery and development of bortezomib (Velcade®), a proteasome inhibitor for cancer therapy. Vito earned his B.S. from Rutgers University and an M.S. and Ph.D. from the New York University Medical Center.
Lisa is an Entrepreneur in Residence focused on global regulatory strategy. Prior to joining Atlas, Lisa was the Vice President of Regulatory Affairs at Zafgen, Inc., where she was responsible for the development and execution of the global regulatory strategy for products to treat metabolic diseases and partnered with the executive team on business strategy. Before Zafgen, Lisa worked for Bristol-Myers Squibb in Clinical Development and Global Regulatory Strategy & Policy, where she led teams in Virology, Immunoscience and Fibrosis to successful completion of clinical trials and IND, NDA, MAA and other global submissions and approvals. She also provided pediatric policy and development expertise for product teams across the portfolio.
Atlas Advisor; Chief Scientific Officer, Cadent Therapeutics
Tim is the CSO at Cadent and has passionately pursued the discovery and development of neuroscience therapeutics for almost two decades in big pharma and in biotech, most notably at AstraZeneca and FORUM Pharmaceuticals. There, he led neuropharmacology teams and both NMDA and nicotinic receptor drug discovery projects and product development teams from lead optimization through Phase 2 trials. Tim leverages collaborative scientific insight and quantitative translational pharmacology to find innovative paths to discover and develop potential breakthrough medicines. Tim earned his Ph.D. in pharmacology from the University of Minnesota.
Simon is an EIR at Atlas. Prior to joining Atlas, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Simon brings to Atlas more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Simon is a Fellow of the Royal Society of Medicine (UK) and a board member of Oxstem Therapeutics. He obtained his Ph.D from University of Hertfordshire and studied Physiology at the University of Manchester in the UK. Simon is well published, having authored over 50 articles in peer reviewed journals.
Atlas Advisor; Chief Executive Officer, Translate Bio
Ron is chief executive officer of Translate Bio. He was previously president and chief executive officer of Idenix Pharmaceuticals, which he refocused on drug discovery and development, resulting in its acquisition by Merck in August 2014. Prior to Idenix, Ron served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, and before that he was a biotechnology equity research analyst at JP Morgan, Schwab Soundview, and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations, and finance.
Atlas Advisor; Former President & Chief Executive Officer, Rodin Therapeutics
Adam was president and CEO of Rodin Therapeutics, and member of the Board of Directors, until the acquisition of Rodin by Alkermes in 2019. Adam has co-founded numerous companies, including Teleos Therapeutics, where he is CEO and director, as well as Link Medicine and Clean Membranes. He has also served in interim executive and strategic advisory roles with numerous healthcare and technology companies, including Brightstar (acquired by SoftBank) and Gecko Health Innovations (acquired by Teva Pharmaceuticals). Previously Adam co-founded Faber Law Group, a boutique business law firm focused on the biotechnology sector, and was a principal with Ovation Capital Partners, an early-stage technology venture fund.
Atlas Advisor; Board Director, Sophren Therapeutics
Mark is a board director for Sophren Therapeutics. Prior to this, he was Head of Neuroscience for Shire, leading teams across multiple therapeutic areas in the US, Europe, Canada, and Japan. Mark also helped lead the preparation for the planned spin of Shire’s Neuroscience Division into a separate listed neuropsychiatry company. He also has a background in Canadian public policy, where he served in multiple advisory roles on both the Minister of State’s staff, as well as the Prime Minister of Canada’s federal election campaign team. Mark obtained his MSc from the London School of Economics, and his BA (Hons.) from the University of Western Ontario. He also serves on the board of the Boys and Girls Club.
Entrepreneur-in-Residence; Vice President of Strategy and Portfolio Development, Generation Bio
Phillip is VP of strategy and portfolio development at Generation Bio. He was previously a principal at Atlas and worked closely with the founding teams of Generation Bio, HotSpot Therapeutics, and others. Prior to Atlas, Phillip was a director at the Merck Research Labs Venture Fund. Before that, he was an associate at Flagship Ventures and was involved in building several startups including Codiak BioSciences, Indigo, and Axcella Health. Previously, Phillip worked in the Center for Systems Biology at UCSD with Jeff Hasty. Phillip graduated from MIT with dual SB degrees in Biological Engineering and Physics, and earned his PhD in Systems Biology from UCSD, where he was a NSF graduate research fellow.
Atlas Advisor; Chief Executive Officer, IFM Therapeutics
Martin CEO of IFM Therapeutics. Previously, Martin was the Global Head of Strategic Alliances for the Novartis Institutes for Biomedical Research (NIBR) where he and his team executed more than 70 deals. Prior to that, Martin was head of NIBR’s Genomics Institute of the Novartis Research Foundation (GNF), where he helped advance over 40 clinical candidates, including 25 programs that progressed to the clinic, 13 new molecular entities that achieved positive clinical proof of concept and two marketed drugs. Martin earned his Ph.D. from Harvard University in the laboratory of Jeremy R. Knowles. He was a DAAD Fellow at the Friedrich-Alexander Universität Erlangen-Nürnberg and received his A.B. from Princeton University.
Atlas Advisor; CEO, Disarm Therapeutics
Alvin is an Atlas Advisor and the CEO of Disarm Therapeutics. Before joining Disarm, he was CEO of Enzyvant, a development-stage rare disease biotechnology company. Prior to Enzyvant, Alvin was the head of R&D at Retrophin. Earlier in his career, he was a founder of Pfizer’s rare disease research unit. He was also previously a management consultant for L.E.K. Consulting and McKinsey & Company. Alvin holds an M.D. from the University of Alabama and an MBA from the Kellogg School of Management. He completed his residency training in internal medicine at Massachusetts General Hospital.
Pete is an EIR at Atlas. He was formerly CSO at H3 Biomedicine where he led a team of scientists discovering and developing novel targeted oncology therapies. He was previously at Millennium Pharmaceuticals/Takeda Oncology where he held positions of increasing responsibility in the oncology group. Peter completed his postdoctoral studies at the Dana-Farber Cancer Institute and the University of Leeds, U.K and obtained his PhD at the Cancer Research Unit, University of Newcastle upon Tyne, U.K.
Atlas Advisor; Chief Scientific Officer, Generation Bio
Matt is CSO at Generation Bio. Previously, he served as VP, head of chemistry and immunology at Moderna where he led nucleotide and delivery chemistry as well as basic platform immunology in support of mRNA therapeutics discovery. Before that, Matt was Director and head of RNA medicinal chemistry at Merck, spending 16 years in roles of increasing leadership, including small molecule program leadership and head of chemistry capabilities enhancement, across numerous therapeutic areas that spanned a range of modalities. Matt graduated from Virginia Tech with a B.S. in chemistry and earned his Ph.D. in chemistry from the University of North Carolina at Chapel Hill with a focus on physical organic chemistry and natural product synthesis.
Atlas Advisor; Chief Development Officer, Obsidian Therapeutics
Catherine is Chief Development Officer at Obsidian Therapeutics, and board member at Dyne Therapeutics. Catherine was previously Chief Medical Officer at Disarm Therapeutics and Dyne Therapeutics, and before that was CMO at Sarepta Therapeutics which focuses on RNA-targeted therapeutics. Prior to Sarepta, she was Vice President, Clinical Development at Regeneron Pharmaceuticals. She also served as Vice President, Global Development at Amgen, leading several therapeutic areas. Catherine earned her M.D. from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an MS degree in Epidemiology. Catherine served as a faculty member in the Division of Nephrology and remains and Affiliate Associate Professor in the School of Public Health with more than 90 publications in medical journals.
Atlas Advisor; Founder and Chief Scientific Officer, Dyne Therapeutics
Romesh is an Atlas Advisor, and founder and CSO of Dyne Therapeutics. Prior to joining Atlas he led Discovery Research at Alexion focusing on Nucleic acid, Antibody and Enzyme replacement therapies. He is a co-founder of RaNA Therapeutics and brings extensive discovery and translational experience in rare disease research from startups and large pharma. Romesh holds an M.S. from Duke University and a Ph.D. from Emory University. He is a member of the advisory board of the Harvard Institute for RNA Medicine.
Atlas Advisor; Head of Platform, Obsidian Therapeutics
Vipin is the head of platform at Obsidian Therapeutics, co-founder of NiDares, and consulting biologist for a number of Atlas Venture seed investments. Prior to joining Atlas, Vipin was director and head of pharmacology at Sirtris, a GlaxoSmithKline company, and before that he worked in the cardiovascular and metabolic diseases group at Pfizer.
Steve is an EIR at Atlas. He started his career in clinical research in the 90’s and held leadership positions in Clinical Operations and Clinical Technology at Pfizer and Infinity Pharmaceuticals before making the move to start-ups. Since 2012 he has worked as Head of Development Operations at several Atlas seeded companies including Arteaus Therapeutics (migraine), Annovation BioPharma (sedation and general anesthesia), Quartet (pain) and Rodin Therapeutics (synaptopathies). His experience spans Phase 1 first-in-human through Phase 3b global registration studies and includes the design and implementation of technology to improve trial analytics and processes. Steve earned his bachelor’s degree in Toxicology from Northeastern University.
Entrepreneur-in-Residence; Chief Technology Officer and Co-Founder, Quench Bio
Mark is an EIR and Co-Founder and CTO of Quench Bio. Formerly Mark was VP, Head of Drug Discovery at Quartet Medicine. Mark has >23 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor. He was previously VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics. Prior to that, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry and Global Head of Operations for the discovery chemistry group. He obtained his Ph.D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.
Entrepreneur-in-Residence; Chief Executive Officer, Quench Bio
Sam is an EIR and and CEO of Quench Bio. Previously she was chief business officer of Padlock Therapeutics until its sale to BMS in March 2016, and advisor to various Atlas portfolio companies. She has more than 20 years of experience in the biotech industry. At Biogen Idec, Sam served as vice president in the corporate development group, and also served as program lead for multiple preclinical and launch-stage products. Prior to Biogen Idec, Sam led licensing and M&A transactions across multiple business units of Genzyme.
Atlas Advisor; Vice President and Head of Chemistry, Disc Therapeutics
Srikanth is an Atlas Advisor and is vice president and head of chemistry at Disc Therapeutics. Prior to joining Atlas, he has more than 19 years of experience in medicinal chemistry and drug discovery working in Schering Plough and Merck leading chemistry teams. He has worked in number of programs in infectious and cardiometabolic diseases. He was a major contributor to the discovery Victrelis, the first HCV NS3 protease inhibitors approved for the treatment of gt-1 infections. He was awarded the Heroes of Chemistry award by the American chemical society for this contribution. Srikanth holds a Ph.D from the University of Pittsburgh and a postdoctoral training from University of Illinois at Urbana Champaign.
Atlas Advisor; Chief Scientific Officer, Admirx
Shelia is CSO of Admirx. She is a leader in the field of inflammation, autoimmune disease and fibrosis with deep industry experience in translational research and drug development. She was previously VP of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery science and advanced programs into clinical development. From 2008 to 2012, Shelia was VP of Research at Stromedix and led all research activities supporting the development of the anti-avb6 antibody, STX-100. She has authored more than 90 manuscripts and patents. Shelia received her Ph.D. in Pharmacology from Yale University and completed her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.
Atlas Advisor; President and Chief Scientific Officer, Navitor Pharmaceuticals
George is president and chief scientific officer of Navitor Pharmaceuticals. He is a scientifically trained executive with nearly 30 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. Most recently George served as CEO of Sirtris from 2009 to 2013. Before that, he held various scientific leadership positions at Wyeth, Corvas International, Merck & Co., and California Biotechnology. He is the author of more than 100 peer-reviewed scientific publications, book chapters, and reviews, and 38 issued U.S. and foreign patents.
Entrepreneur-in-Residence; Chief Medical Officer, Third Harmonic Bio
Stephen is Chief Medical Officer of Third Harmonic Bio. Previously, Stephen was the first CMO at Regenxbio and helped advance a pipeline focused on developing AAV gene therapies for retinal, metabolic and neurodegenerative diseases. Prior to Regenxbio, he held multiple roles in clinical development within MedImmune/AstraZeneca and Abbott Labs within the autoimmunity and inflammation group. Stephen earned his B.A. in molecular genetics from the University of California, Berkeley, his M.D. from the University of California, Los Angeles and he completed his residency in dermatology at the University of Texas, Southwestern.